SVRA
SavaraยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
SVRA Profile
Savara Inc.
A biopharmaceutical company that develops and commercializes therapies for rare respiratory diseases
1717 Langhorne Newtown Road, Suite 300 Langhorne, Pennsylvania 19047
--
Savara Inc., a Delaware corporation, is a biopharmaceutical company engaged in the development of treatments for serious or life-threatening diseases. The Company has been dedicating the vast majority of its resources to research and development (" R&D ") and the acquisition of its product candidates. The company has not yet listed or sold any products or generated any significant revenue. In 2011, through the Company's acquisition of SynthRx Co., Ltd., the Company acquired the Company's membrane adhesion and sealant technology platform, which includes proprietary poloxam-related data and developed knowledge with more than 20 years of clinical, non-clinical and manufacturing experience, and the Company is utilizing the MST -188 developed by the Master platform to treat diseases characterized by microcirculatory insufficiency conditions. In previous years, the company was developing Exelbine and ANX-514, both of which are investigational oncology programs, but at the beginning of 2012, the company has focused its resources almost entirely on the development of MST-188.
The company was incorporated in Delaware in December 1995.
